AGO Ovar 22: A Phase III, multicenter, randomized, study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin and Bevacizumab to patients with newly diagnosed Stage III or Stage IV ovarian, Fallopian Tube or primary Peritoneal Cancer
Laufzeit: 01.01.2018 - 31.12.2025